Cargando…
A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus
Influenza A virus (IAV) causes significant morbidity and mortality, despite the availability of viral vaccines. The efficacy of live attenuated influenza vaccines (LAIVs) has been especially poor in recent years. One potential reason is that the master donor virus (MDV), on which all LAIVs are based...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997774/ https://www.ncbi.nlm.nih.gov/pubmed/31748399 http://dx.doi.org/10.1128/JVI.01065-19 |
_version_ | 1783493748306477056 |
---|---|
author | Smith, Andrew Rodriguez, Laura El Ghouayel, Maya Nogales, Aitor Chamberlain, Jeffrey M. Sortino, Katherine Reilly, Emma Feng, Changyong Topham, David J. Martínez-Sobrido, Luis Dewhurst, Stephen |
author_facet | Smith, Andrew Rodriguez, Laura El Ghouayel, Maya Nogales, Aitor Chamberlain, Jeffrey M. Sortino, Katherine Reilly, Emma Feng, Changyong Topham, David J. Martínez-Sobrido, Luis Dewhurst, Stephen |
author_sort | Smith, Andrew |
collection | PubMed |
description | Influenza A virus (IAV) causes significant morbidity and mortality, despite the availability of viral vaccines. The efficacy of live attenuated influenza vaccines (LAIVs) has been especially poor in recent years. One potential reason is that the master donor virus (MDV), on which all LAIVs are based, contains either the internal genes of the 1960 A/Ann Arbor/6/60 or the 1957 A/Leningrad/17/57 H2N2 viruses (i.e., they diverge considerably from currently circulating strains). We previously showed that introduction of the temperature-sensitive (ts) residue signature of the AA/60 MDV into a 2009 pandemic A/California/04/09 H1N1 virus (Cal/09) results in only 10-fold in vivo attenuation in mice. We have previously shown that the ts residue signature of the Russian A/Leningrad/17/57 H2N2 LAIV (Len LAIV) more robustly attenuates the prototypical A/Puerto Rico/8/1934 (PR8) H1N1 virus. In this work, we therefore introduced the ts signature from Len LAIV into Cal/09. This new Cal/09 LAIV is ts in vitro, highly attenuated (att) in mice, and protects from a lethal homologous challenge. In addition, when our Cal/09 LAIV with PR8 hemagglutinin and neuraminidase was used to vaccinate mice, it provided enhanced protection against a wild-type Cal/09 challenge relative to a PR8 LAIV with the same attenuating mutations. These findings suggest it may be possible to improve the efficacy of LAIVs by better matching the sequence of the MDV to currently circulating strains. IMPORTANCE Seasonal influenza infection remains a major cause of disease and death, underscoring the need for improved vaccines. Among current influenza vaccines, the live attenuated influenza vaccine (LAIV) is unique in its ability to elicit T-cell immunity to the conserved internal proteins of the virus. Despite this, LAIV has shown limited efficacy in recent years. One possible reason is that the conserved, internal genes of all current LAIVs derive from virus strains that were isolated between 1957 and 1960 and that, as a result, do not resemble currently circulating influenza viruses. We have therefore developed and tested a new LAIV, based on a currently circulating pandemic strain of influenza. Our results show that this new LAIV elicits improved protective immunity compared to a more conventional LAIV. |
format | Online Article Text |
id | pubmed-6997774 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-69977742020-02-11 A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus Smith, Andrew Rodriguez, Laura El Ghouayel, Maya Nogales, Aitor Chamberlain, Jeffrey M. Sortino, Katherine Reilly, Emma Feng, Changyong Topham, David J. Martínez-Sobrido, Luis Dewhurst, Stephen J Virol Vaccines and Antiviral Agents Influenza A virus (IAV) causes significant morbidity and mortality, despite the availability of viral vaccines. The efficacy of live attenuated influenza vaccines (LAIVs) has been especially poor in recent years. One potential reason is that the master donor virus (MDV), on which all LAIVs are based, contains either the internal genes of the 1960 A/Ann Arbor/6/60 or the 1957 A/Leningrad/17/57 H2N2 viruses (i.e., they diverge considerably from currently circulating strains). We previously showed that introduction of the temperature-sensitive (ts) residue signature of the AA/60 MDV into a 2009 pandemic A/California/04/09 H1N1 virus (Cal/09) results in only 10-fold in vivo attenuation in mice. We have previously shown that the ts residue signature of the Russian A/Leningrad/17/57 H2N2 LAIV (Len LAIV) more robustly attenuates the prototypical A/Puerto Rico/8/1934 (PR8) H1N1 virus. In this work, we therefore introduced the ts signature from Len LAIV into Cal/09. This new Cal/09 LAIV is ts in vitro, highly attenuated (att) in mice, and protects from a lethal homologous challenge. In addition, when our Cal/09 LAIV with PR8 hemagglutinin and neuraminidase was used to vaccinate mice, it provided enhanced protection against a wild-type Cal/09 challenge relative to a PR8 LAIV with the same attenuating mutations. These findings suggest it may be possible to improve the efficacy of LAIVs by better matching the sequence of the MDV to currently circulating strains. IMPORTANCE Seasonal influenza infection remains a major cause of disease and death, underscoring the need for improved vaccines. Among current influenza vaccines, the live attenuated influenza vaccine (LAIV) is unique in its ability to elicit T-cell immunity to the conserved internal proteins of the virus. Despite this, LAIV has shown limited efficacy in recent years. One possible reason is that the conserved, internal genes of all current LAIVs derive from virus strains that were isolated between 1957 and 1960 and that, as a result, do not resemble currently circulating influenza viruses. We have therefore developed and tested a new LAIV, based on a currently circulating pandemic strain of influenza. Our results show that this new LAIV elicits improved protective immunity compared to a more conventional LAIV. American Society for Microbiology 2020-01-31 /pmc/articles/PMC6997774/ /pubmed/31748399 http://dx.doi.org/10.1128/JVI.01065-19 Text en Copyright © 2020 Smith et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Vaccines and Antiviral Agents Smith, Andrew Rodriguez, Laura El Ghouayel, Maya Nogales, Aitor Chamberlain, Jeffrey M. Sortino, Katherine Reilly, Emma Feng, Changyong Topham, David J. Martínez-Sobrido, Luis Dewhurst, Stephen A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus |
title | A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus |
title_full | A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus |
title_fullStr | A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus |
title_full_unstemmed | A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus |
title_short | A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus |
title_sort | live attenuated influenza vaccine elicits enhanced heterologous protection when the internal genes of the vaccine are matched to those of the challenge virus |
topic | Vaccines and Antiviral Agents |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997774/ https://www.ncbi.nlm.nih.gov/pubmed/31748399 http://dx.doi.org/10.1128/JVI.01065-19 |
work_keys_str_mv | AT smithandrew aliveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT rodriguezlaura aliveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT elghouayelmaya aliveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT nogalesaitor aliveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT chamberlainjeffreym aliveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT sortinokatherine aliveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT reillyemma aliveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT fengchangyong aliveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT tophamdavidj aliveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT martinezsobridoluis aliveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT dewhurststephen aliveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT smithandrew liveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT rodriguezlaura liveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT elghouayelmaya liveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT nogalesaitor liveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT chamberlainjeffreym liveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT sortinokatherine liveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT reillyemma liveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT fengchangyong liveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT tophamdavidj liveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT martinezsobridoluis liveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus AT dewhurststephen liveattenuatedinfluenzavaccineelicitsenhancedheterologousprotectionwhentheinternalgenesofthevaccinearematchedtothoseofthechallengevirus |